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Abstract
Background: An influence of gonadotropins (hCG) on the development of ovarian cancer has been discussed.
Therefore, we quantified serum hCG levels in patients with benign and malignant ovarian tumors and the hCG
expression in ovarian cancer tissue in order to analyze its relation to grade, stage, gonadotropin receptor (LH-R,
FSH-R) expression and survival in ovarian cancer patients.
Methods: Patients diagnosed and treated for ovarian tumors from 1990 to 2002 were included. Patient
characteristics, histology including histological subtype, tumor stage, grading and follow-up data were available.
Serum hCG concentration measurement was performed with ELISA technology, hCG tissue expression determined
by immunohistochemistry.
Results: HCG-positive sera were found in 26.7% of patients with benign and 67% of patients with malignant
ovarian tumors. In addition, significantly higher hCG serum concentrations were observed in patients with
malignant compared to benign ovarian tumors (p = 0.000). Ovarian cancer tissue was positive for hCG expression
in 68%. We identified significant differences in hCG tissue expression related to tumor grade (p = 0.022) but no
differences with regard to the histological subtype. In addition, mucinous ovarian carcinomas showed a
significantly increased hCG expression at FIGO stage III compared to stage I (p = 0.018). We also found a positive
correlation of hCG expression to LH-R expression, but not to FSH-R expression. There was no significant correlation
between tissue hCG expression and overall ovarian cancer patient survival, but subgroup analysis revealed an
increased 5-year survival in LH-R positive/FSH-R negative and hCG positive tumors (hCG positive 75.0% vs. hCG
negative 50.5%).
Conclusions: Serum human gonadotropin levels differ in patients with benign and malignant ovarian tumors. HCG
is often expressed in ovarian cancer tissue with a certain variable relation to grade and stage. HCG expression
correlates with LH-R expression in ovarian cancer tissue, which has previously been shown to be of prognostic
value. Both, the hormone and its receptor, may therefore serve as targets for new cancer therapies.
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Due to missing early clinical symptoms, ovarian cancer
is often diagnosed at an advanced stage [1]. Primary
treatment includes operative cytoreduction and subse-
quent combined platinum-based chemotherapy. Though
reported primary response rates range around 80%,
ovarian cancer is the most lethal gynecological malig-
nancy since 60-70% of patients relapse or die within 5
years after primary diagnosis [2-4].
The molecular mechanism of ovarian cancer develop-
ment is still discussed controversially [5]. As ovaries are
the target organs of gonadotropins, a relation to the
development or growth of ovarian cancer has been pos-
tulated [6]. An increased risk for the development of
ovarian cancer was assumed in women treated for infer-
tility who had therefore been stimulated with gonado-
tropins [7-9].
Human gonadotropin (hCG) is expressed in placental
trophoblasts, but also in a large number of tumors.
HCG and the gonadotropin luteal hormone (LH) bind
to the same receptor (LH-R) and have similar biological
functions, although hCG is more potent because of its
higher receptor binding affinity and its longer circula-
tory half life. Human chorionic gonadotropin is a glyco-
protein produced by the fetal trophoblast during
pregnancy and is secreted into the maternal circulation
[10]. The commitment of cytotrophoblasts to syncytio-
trophoblasts is associated with activation of a-a n db-
hCG subunit genes [11]. These intermediates are transi-
ent, they differentiate to syncytiotrophoblasts and the
expression of b-hCG RNA declines [12]. Also in chorion
carcinoma cells consisting of clusters of cytotrophoblast-
like and large multinucleated cells, a-a n db-hCG RNA
is expressed [13]. In these cells, hCG has been used as a
tumor marker for a long time [14].
There are only few studies with small patient numbers
on human chorionic gonadotropin and its receptor
expression in ovarian cancer tissue [15,16]. In a previous
s t u d yw ef o u n dap r o g n o s t i cv a l u eo fL H - Ra n dF S H - R
in ovarian cancer patients [17]. The present study was
designed to further analyze hCG expression in a large
cohort of ovarian cancer patients and its relation to his-
tological subtype, grade, stage, gonadotropin receptor
expression and patient survival. In addition, we deter-
mined hCG serum concentrations in patients with ovar-
ian cancer and compared the results to patients with
benign ovarian tumors.
Methods
Sera
Sera of patients diagnosed with an ovarian tumor
between 2003 and 2006 were obtained before surgery
and stored at -80°C. After surgery, histological diagnos-
tic evaluation including staging and grading of tumor
tissue were performed by an experienced gynecologic
pathologist (D.M.) according to the criteria of the Inter-
national Federation of Gynaecologists and Obstetricians
(FIGO) and the World Health Organization (WHO).
Tissue samples
All tissue samples were gained at surgery in patients
who had been treated for primary ovarian cancer at our
institution between 1990 and 2002. Staging and grading
were performed by an experienced gynecologic patholo-
gist according to the criteria of the International Federa-
tion of Gynaecologists and Obstetricians (FIGO) and the
World Health Organization (WHO). Patients with ovar-
ian borderline tumor were excluded from the study.
Clinical data of the patients’ disease were available from
patient charts, aftercare files and tumor registry database
information. The main outcomes assessed were disease
recurrence and patient survival.
Ethics approval
The study has been approved by the local ethics com-
mittee of the Ludwig-Maximilians University Munich
(approval with the reference number 138/03) and has
been carried out in compliance with the guidelines of
the Helsinki Declaration of 1975. The study participants
gave their written informed consent and samples and
clinical information were used anonymously.
hCG-ELISA
Concentration of hCG was obtained by an ELISA and
using the Immulite 2000 automated diagnostic system
(Siemens, Munich, Germany). Standard deviation for
precision at 6.5 m IU/ml is 0.43 with a variation coeffi-
cient (CV) of 6.6%. Precision analysis showed no cross
reactivity with human FSH (26.8 ng/ml analyzed), LH
(16.5 ng/ml analyzed) or TSH (860 ng/ml analyzed).
Immunohistochemistry was performed as previously
described elsewhere, using a combination of pressure
cooker heating and the standard streptavidin-biotin-per-
oxidase complex with the use of the rabbit-IgG-Vectas-
tain Elite ABC kit (Vector Laboratories, Burlingame,
CA) [18,19]. Antibodies used for staining were the anti-
hCG (17.75 μg/ml, rabbit IgG, polyclonal, dilution 1:400,
Dako, Glostrup, Denmark) and anti-LH (LH/hCG-R, 1
mg/ml, rabbit IgG, polyclonal, dilution 1:25, Dianova,
Hamburg, Germany).
In short, paraffin-fixed tissue sections were dewaxed
with xylol for 15 min and then dehydrated in ascending
concentrations of alcohol (70%, 96%, and 100%). After-
wards, they were exposed for epitope retrieval for 10
min in a pressure cooker using sodium citrate buffer
(pH 6.0) containing 0.1 M citric acid and 0.1 M sodium
citrate in distilled water. After cooling, slides were
washed in PBS twice. Endogenous peroxidase activity
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(Merck, Darmstadt, Germany) in methanol for 20 min.
Non-specific binding of the primary antibodies was
blocked by incubating the sections with “diluted normal
serum” (10 ml PBS containing 150 μl horse serum; Vec-
tor Laboratories, CA) for 20 min at room temperature.
Then, slides were incubated with the primary antibodies
at room temperature for 60 min. After washing with
PBS, slides were incubated in “diluted biotinylated
serum” (10 ml PBS containing 50 μlh o r s es e r u m ;V e c -
tor Laboratories, CA) for 30 min at room temperature.
After incubation with the avidin-biotin-peroxidase com-
plex (diluted in 10 ml PBS, Vector Laboratories, CA) for
30 min and repeated PBS washing, visualization was
conducted using substrate and chromagen 3,3’-diamino-
benzidine (DAB; Dako, Glostrup, Denmark) for 8-10
min. Slides were then counterstained with Mayer’s
acidic hematoxylin and dehydrated in ascending concen-
trations of alcohol (50-98%). After xylol treatment, slides
were covered.
Placental tissue at 3rd trimenon served as a positive
control for the hCG and LH-R staining, accordingly. For
negative controls, primary antibody was replaced with
normal control serum rabbit IgG (BioGenex, San
Ramon, USA). Positive staining resulted in brownish
color, negative controls as well as unstained cells in blue
color.
Immunohistochemical analysis
Slides were evaluated and digitalized with a Zeiss photo-
microscope (Axiophot, Axiocam, Zeiss, Jena, Germany).
Immunohistochemical staining was assessed using a
semiquantitative score according to Remmele and
Stegner [20], comprising optical staining intensity
(graded as 0 = no, 1 = weak, 2 = moderate, and 3 =
strong staining) and the percentage of positively stained
cells (0 = no, 1 = < 10%, 2 = 11-50%, 3 = 51-80% and 4
= > 81% cells). According to previously published data,
we scored the tumor tissue as positive if more than 10%
of cells were scored with an immunoreactive score (IRS)
higher than 2 [15]. The slides were reviewed in a
blinded fashion by two independent observers, including
a gynecological pathologist (D.M.).
Statistical analysis
Statistical analysis was performed using SPSS 18.0
(PASW Statistic, SPSS Inc., IBM, Chicago, IL). Correla-
tion analysis of the receptor expression was performed
for the histological subtype, tumor stage, grading and
clinical data using the non-parametric Kruskal-Wallis
rank-sum test and the non-parametric Spearman corre-
lation coefficient. For the comparison of survival times,
Kaplan-Meier curves were drawn. The chi-square statis-
tic of the log-rank test was calculated to test differences
between survival curves for significance. P values below
0.05 were considered statistically significant.
Results
Patient characteristics
Sera of 123 patients diagnosed with either benign (n =
83) or malignant (n = 40) ovarian tumors were obtained
before surgery to test for serum hCG levels. Among the
patients with benign ovarian tumors were cystadenomas
(n = 12), simple ovarian cysts (n = 25), endometriosis (n
= 9), teratomas (n = 10), fibromas (n = 8) and other
tumors (n = 18). Patients with ovarian carcinomas mostly
presented at stage III or IV (FIGO I: 15.4%, FIGO II:
11.5%, FIGO III: 53.8% and FIGO IV: 19.2%). Patients
with borderline tumors of the ovary are neither included
in the benign nor in the ovarian cancer patient group.
Paraffin embedded tissue of 156 ovarian cancer
patients was available. Median age at primary diagnosis
was 58 years (range 18-88). Most patients presented
with progressed disease at primary diagnosis [FIGO I: n
= 35 (22.6%), FIGO II: n = 9 (5.8%), FIGO III: n = 109
(70.3%), FIGO IV: n = 2 (1.3%)]. Patient characteristics
are detailed in Table 1. Median follow-up time was 7.3
years (range 0.3-16.8) with 26 documented relapses and
91 deaths. Median relapse free survival was 2.1 years
(range 0.9-7.2) and median overall survival 5.9 years
(range 0.3-16.6) (Table 1).
hCG ELISA
In serum analysis, we found hCG-positive sera in 26.7%
of patients with benign ovarian tumors and 67% positive
sera in patients with malignant ovarian tumors. In addi-
tion, we identified significant differences in hCG con-
centration in benign compared to malignant diseases of
the ovaries (p = 0.000). The median calculation has
been done using all samples, i.e. negative samples were
also included in the calculation. Median hCG concentra-
tion in patient sera with benign ovarian tumors was 0.1
mU/ml and 4 mU/ml in patients with malign ovarian
tumors (Figure 1).
hCG expression in ovarian cancer tissue
Immunohistochemical analysis revealed hCG positive
tumors in 68% of all cancer tissues investigated (Figure
2a, b). Only slight differences in hCG expression could
be observed with respect to the histological subtype,
with lowest expression in clear cell carcinomas and
highest in mucinous ovarian carcinomas (Figure 3a).
Regarding tumor grade, we identified significant differ-
ences in hCG expression among G1, G2 and G3 carci-
nomas (Figure 3b, p = 0.022). With respect to tumor
stage, a significant difference was observed in mucinous
tumors at stage FIGO I compared FIGO II and FIGO
III (p = 0.018, Figure 3c).
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receptor expression (correlation coefficient 0.194, p =
0.037, Table 2) was identified. Interestingly, there was
no correlation of hCG expression and FSH-receptor
expression.
Prognostic value of hCG
Statistical analysis was performed to test for a prognos-
tic value of hCG expression in ovarian cancer tissue.
The univariate Kaplan Meier analysis reveals no statisti-
cal difference between patients positive and negative for
hCG in ovarian cancer tissue (p = 0.618). Interestingly,
there was an increased 5-year survival in patients with
hCG positive tumors in the LH-R positive/FSH-R nega-
tive subgroup (5-year survival: hCG positive 75.0% vs.
hCG negative 50.5%; Figure 4, Table 3).
Table 1 Patient characteristics of ovarian cancer patients whose tissue samples were stained by
immunohistochemistry for hCG expression or serum samples were analyzed for hCG concentration
Tissue samples Serum samples
Ovarian cancer patients (n) 156 40
Age at primary diagnosis (a) 58 (range 18-88) 62 (range 21-80)
Histology (%) serous 70.5 81.0
mucinous 13.5 4.8
endometrioid 7.7 14.3
clear cell 8.3 0.0
Tumor grading (%) low grade 27.2 4.2
intermediate 36.5 54.2
high grade 36.3 51.7
Tumor stage (FIGO) (%) I 22.6 13.9
II 5.8 13.9
III 70.3 55.6
IV 1.3 16.7
Gonadotropin receptor expression (%) LH-R positive 64.3 -
FSH-R positive 63.1 -
Figure 1 Determination of hCG in sera of patients with
diagnosed benign or malign diseases of the ovaries before
surgery shown in boxplots. The boxes represent the range
between the 25th and 75th percentiles with a horizontal line at the
median. The bars delineate the 5th and 95th percentiles. The circle
indicate values more than 1.5 box lengths, and the asterisk values
more than 3.0 box lengths from the 75th percentile. Numbers at
circle and asterisk indicate sample number. hCG levels were
significantly lower in patients with benign compared to patients
with malign diseases of the ovaries (p = 0.000).
Figure 2 Representative slides of immunohistochemical
staining for hCG expression for FIGO stage II (a, hCG negative),
FIGO stage III (b, hCG positive) for grade 1 (c, weak hCG
staining) and grade 2 (d, strong hCG staining) ovarian cancer
tissue. No hCG immunoreactivity was detected in tumor stroma
(magnification 10× and 25×).
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To date, the pathogenesis and progression of ovarian
cancer remains unclear. There are various hypotheses to
explain its etiology, two of them discussing hormonal
influence on tumorgenesis [6,21-23]. Some risk factors
for the development of ovarian cancer like nulliparity
and infertility have been identified in epidemiologic stu-
dies [21,24-26]. Ovarian cancer is often diagnosed in
postmenopausal women who present with high gonado-
tropin blood serum levels [27]. Until today, the influence
of hormones, especially gonadotropins, on the develop-
ment or progression of ovarian cancer remains under
discussion [23,27,28].
In this study, serum human gonadotropin (hCG) levels
differ between patients with benign and malignant ovar-
ian tumors. HCG and its subunits can be measured at
low dose in the serum of most men and women [29]. Its
values differ according to the level of gonadotropin
r e l e a s i n gh o r m o n e[ 3 0 ]a n di ti sa s s u m e dt h a tm o s to f
hCG in serum of healthy persons originates from the
pituitary. Studies on hCG-immonoreactivity have
demonstrated that hCG is often elevated in serum of
Figure 3 Expression of hCG in ovarian cancer shown in
boxplots. a Expression of hCG in ovarian cancer subtypes shown in
boxplots. The boxes represent the range between the 25th and
75th percentiles with a horizontal line at the median. The bars
delineate the 5th and 95th percentiles. There were no significant
differences in hCG expression between serous, clear cell,
endometrioid or mucinous forms of ovarian cancer. b Expression of
hCG in all ovarian cancer subtypes shown in boxplots regarding to
grading. We identified significant differences in G1, G2 and G3
carcinomas (p = 0.022). The boxes represent the range between the
25th and 75th percentiles with a horizontal line at the median. The
bars delineate the 5th and 95th percentiles. The circle indicates
values more than 1.5 box lengths. c Expression of hCG in the
mucinous ovarian cancer subtype shown in boxplots regarding to
staging. We identified significant differences in FIGO I, FIGO II and
FIGO III carcinomas (p = 0.018). The boxes represent the range
between the 25th and 75th percentiles with a horizontal line at the
median. The bars delineate the 5th and 95th percentiles.
Table 2 Correlation between hCG, LH-receptor and FSH-receptor expression in all ovarian cancer subtypes
Correlations
hCG (Int) hCG (IRS) LH-R (Int) LH-R (IRS) FSH-R (Int) FSH-R (IRS)
Spearman’s rho hCG (Int) Correlation Coefficient 1.00 0.94** 0.13 0.19* -0.09 0.01
Sig. (2-tailed) < 0.01 0.04
hCG (IRS) Correlation Coefficient 0.94** 1.00 0.12 0.19* -0.01 0.09
Sig. (2-tailed) < 0.01 0.04
N (Int/IRS) 143 143 116 116 114 113
LH-R (Int) Correlation Coefficient 0.13 0.12 1.00 0.90** 0.23* 0.23*
Sig. (2-tailed) < 0.01 0.01 0.01
LH-R (IRS) Correlation Coefficient 0.19* 0.19* 0.90** 1.00 0.21* 0.24*
Sig. (2-tailed) 0.04 0.04 < 0.01 0.03 0.01
N (Int/IRS) 116 116 120 120 116 115
FSH-R (Int) Correlation Coefficient -0.09 -0.01 0.23* 0.21* 1.00 0.87**
Sig. (2-tailed) 0.01 0.03 0.01
FSH-R (IRS) Correlation Coefficient 0.002 0.09 0.23* 0.24* 0.87** 1.00
Sig. (2-tailed) 0.01 0.01 < 0.01
N (Int/IRS) 113 113 115 115 117 117
We found a significant correlation between hCG and LH-receptor expression whereas hCG expression and FSH-receptor expression do not correlate with each
other. (IRS = immunoreactive score, Int = staining intensity)
** Correlation is significant at the 0.01 level (2-tailed)
* Correlation is significant at the 0.05 level (2-tailed)
Figure 4 Kaplan-Meyer analysis indicating survival in
subgroups of patients with or without hCG expression in
ovarian cancer tissue samples.
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serum levels seem not to be useful in the diagnosis or
therapy monitoring of non-trophoblastic gynecological
malignancies [32,33]. But since there is evidence sup-
porting that hCG is produced by gynecological cancers
themselves [34-36], hCG production can be suspected
to have an influence on gonadotropin receptor expres-
sion in cancer tissue. The fact that we observed a posi-
tive correlation of hCG to LH-receptor expression
supports this assumption.
Among non-trophoblastic cancers, hCG expression is
best analyzed in the transitional cell carcinoma of the
bladder and urinary tract. The appearance of human
chorionic gonadotropin within the tumor cells is
described to be an evidence of dedifferentiation, since it
is more commonly expressed in poorly differentiated
tumors [37]. In this study, we also observed significant
differences in hCG expression related to tumor grade (p
= 0.022) but no differences with regard to the histologi-
cal subtype. In addition, mucinous ovarian carcinomas
showed significantly increased hCG expression at FIGO
stage 3 (p = 0.018). There is in vitro data with uterine
microvascular endothelial cells showing hCG to increase
capillary formation and migration of endothelial cells
with no effect on cell proliferation [38]. In the same
study by Zygmunt et al., hCG was found to induce neo-
v a s c u l a r i z a t i o ne v e ni no v a r i a nc a n c e ri na ni nv i v oa n i -
mal model. Therefore, hCG was thought to be an
important angiogenetic factor [38]. This finding may in
part explain higher hCG expression in dedifferentiated
tumors or higher stages in the mucinous ovarian cancer
subgroup as observed in our own study. Still, there was
no significant difference in patient survival relating to
tumor hCG expression as it was found for transitional
cell cancer of the bladder [39]. Therefore, we assume
hCG to have varying functions in ovarian cancer, e.g.
neovascularization or LH-R regulation, which might
explain the partly contradictory findings of hCG effects
in relation to histological results on the one hand and
patient survival on the other.
Interestingly, we found a difference in 5-year survival
rate between hCG-positive and hCG-negative tumors
depending on LH-R or FSH-R expression. As demon-
strated in our previous study, the LH-R and FSH-R
themselves have prognostic value for patient’ss u r v i v a l
[17]. Our results showed a positive correlation of hCG
tissue expression and LH-R expression. Therefore we
assume hCG also to have an LH-R regulative function.
The role of hCG and its receptors in cancer is discussed
controversially in literature [15,40]. We have demon-
strated here, that the contradictory findings in literature
may also be explained by variable gonadotropin hor-
mone and hormone receptor expression.
Gonadotropins bind to extracellular receptors, the LH-
R and FSH-R. The LH-R receptor binds not only the
gonadotropin LH but also hCG, and is therefore often
referred to as LH/hCG-R. It is mainly found in gonadal
tissue. Apart from gonadal tissue, it is known to be
expressed in a variety of non-gonadal tissues in humans
and rodents, like fetal tissues [41], the placenta [42],
mammary gland [43], the salpinx, the uterus [44] or the
cervix [45]. Most research on this receptor focuses on
fertility-related treatments. Nonetheless, new therapeutic
fields are evolving regarding this receptor since the LH/
hCG-R is expressed in human cancer cells like breast
cancer [46] or ovarian cancer [17]. To reduce the side-
effects of chemotherapy, receptor-mediated therapies
might be a new approach in anticancer treatment. Rah-
man et al. have developed a lytic peptide, hecate-CGbeta,
which selectively kills cancer cells by changing their
membrane potential [47]. Its effect on tumor cells has
already been proven for breast cancer [46-48] and testi-
cular tumors [49], but also for ovarian cancer [49,50].
Gebauer et al. have analyzed the effect of human chor-
ionic gonadotropin-doxorubicin on ovarian cancer cells
and observed an increased activity of doxorubicin when
conjugated to hCG [51]. This finding was also described
for breast cancer cells [52]. The combination of cyto-
static agents with hormones like hCG for the treatment
of LH/hCG-R positive cells might be a promising
approach to reduce morbidity and mortality in antican-
cer therapy. New therapeutic agents like lytic peptides
or chemotherapeutic agents binding to the LH-R offer
less toxic, but effective and selective anticancer treat-
ment options, either alone or in combination with stan-
dard chemotherapeutic agents, in ovarian cancer
patients whose tumors express these receptors.
Strengths of this study are the long follow-up time,
t h ec o n s i s t e n tp a t h o l o g i ch i s t o l o g yr e v i e wb ye x p e r t
gynecologic oncology pathologists and the large sample
size. A limitation of this study is obviously the retro-
spective study design.
Table 3 Ovarian cancer patient survival: 5-year survival for hCG positive and negative tumors with regard to LH
receptor (LH-R) and FSH receptor (FSH-R) expression
Ovarian cancer patient 5-year
survival (%)
LH-R positive and FSH-R
negative
FSR-R and LH-R positive/FSH-R and LH-R
negative
FSH-R positive and LH-R
negative
hCG negative 50.5 44.9 30.0
hCG positive 75.0 39.8 25.0
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Serum human gonadotropin levels differ in patients with
benign and malignant ovarian tumors. HCG is often
expressed in ovarian cancer tissue with a certain variable
relation to grade and stage. HCG expression correlates
with LH-R expression in ovarian cancer tissue, which
has previously been shown to be of prognostic value.
Both, the hormone and its receptor, may therefore serve
as targets for new cancer therapies, which may directly
bind to hCG or its receptor LH-R and increase efficacy
and specificity of anticancer treatment, thus reducing
side effects.
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